How FDA Regulates Wearable Health Devices Between Wellness and Diagnosis

Wearable health devices are regulated by where their claims sit on a line FDA draws between lifestyle encouragement and disease-related intervention: general wellness products fall outside device regulation, while claims to detect or inform clinical management require a premarket pathway. The claim, not the sensor, carries the product across.

What does the general wellness policy actually cover?

FDA's guidance, docketed FDA-2014-N-1039, states its purpose as providing "clarity to industry and FDA staff on the Center for Devices and Radiological Health's (CDRH's) compliance policy for low risk products that promote a healthy lifestyle (general wellness products)," and notes it does not apply to products regulated by other FDA Centers, per the guidance page. The policy rests on the 21st Century Cures Act provision that removed certain healthy-lifestyle software functions from the device definition. In practice, that covers step counters, sleep scores, and exercise coaching — claims about staying well. The moment a claim references a disease state, the product crosses into device territory and the claim, not the hardware, carries it there.

Which pathway applies once a wearable is a device?

Device regulation for wearables is a ladder, and the rungs are determined by risk and precedent.

1. General wellness (no premarket review) — low-risk lifestyle claims only, per the Cures Act carve-out and FDA's compliance policy.
2. 510(k) clearance — the manufacturer shows substantial equivalence to a legally marketed predicate; most ECG-equipped wearables take this route.
3. De Novo classification — for novel devices of low-to-moderate risk without a predicate; it creates a new classification and a future predicate for others.

The ladder explains a pattern readers will recognize: each new sensor category — heart rhythm, blood pressure, temperature — initially needs a heavier pathway, then later products of the same type clear against earlier ones more quickly.

How does a clearance read in practice?

The December 2025 HeartBeam decision shows the mechanics. On December 10, 2025, the company announced FDA 510(k) clearance for its cable-free synthesized 12-lead ECG for at-home arrhythmia assessment — a credit-card-sized device delivering clinical-grade insights directly to patients — after a successful appeal overturning a prior Not Substantially Equivalent outcome, per HeartBeam's press release. The notable regulatory fact is procedural: 510(k) decisions are reviewable through the appeal process, and an NSE determination is not the end of the road when the equivalence argument is restated. The clearance is the company's announcement of the agency's decision; the device's exact cleared claims live in the agency's 510(k) database.

Where is the boundary most often tested?

Two places. First, consumer copy drifting toward clinical claims — marketing that says a feature detects a condition can convert a wellness product into an unclassified device, which is a compliance question, not a software question. Second, software updates: a cleared algorithm's performance claims are fixed to the version reviewed, and meaningful changes generally require a new submission or a new 510(k). The comparison that matters for readers:

What does software change about the review?

Three things, all procedural. First, software functions can be regulated as devices in their own right — Software as a Medical Device — so a wearable's regulated component may be the algorithm rather than the strap or sensor housing it runs on. Second, the review evaluates the algorithm's validation population: for which patients, against which reference standard, with what agreement, in the labeling the sponsor proposed. Third, change control: a cleared algorithm's claims attach to the reviewed version, and sponsors navigate predetermined change protocols or new submissions to ship performance-affecting updates. For readers of clearance announcements, the durable facts are the cleared indication, the predicate where one exists, and the date — all of which live in FDA's public databases rather than the press release.

The working rule: read the claim on the box, not the sensor on the wrist. FDA regulates the sentence, and every pathway question in wearables resolves back to it.

Where is the market pushing the line next?

Toward features that used to be clinic-only. Blood-pressure estimation, temperature trends, and continuous glucose access for non-diabetic wellness uses each sit differently on the boundary: some have predicates and clear through 510(k), some would need new classifications, and some remain wellness claims so long as their labeling avoids disease language. The consistent regulatory fact is that the boundary moves by guidance and clearance precedent, published and dated, rather than by device category. Readers tracking the space should watch three public records — the guidance docket, the De Novo grant list, and the 510(k) database — because every future wearable's regulatory identity will be decided in one of them.

When a new claim appears whose pathway is unclear, the fastest professional check is the labeling: if the claim references a disease or a clinical action, a pathway applies; if it references fitness and lifestyle only, the wellness policy governs. That single reading discipline, applied consistently, resolves most of the confusion that surrounds wearable regulation in industry discussion.

Everything else in the wearable regulatory conversation — category debates, sensor novelty, consumer enthusiasm — is downstream of that sentence-level decision, made first by the sponsor and confirmed or challenged by the agency.